Mermel is Professor of Medicine at the Warren Alpert Medical School of Brown University. Mermel joins Isaam Raad, the chair of MD Anderson Cancer Center's Department of Infectious Diseases (also chairman of the Citius Scientific advisory board), and Mark Rupp, Professor and Chief of the Division of Infectious Diseases at the University of Nebraska Medical Center.
The advisory board will be counseling the company on its development programs, particularly the anti-infective portfolio which includes the company's lead technology, Mino-Lok.
Citius' Mino-Lok product is designed to salvage infected central venous catheters (CVCs) that cause catheter related bloodstream infections (CRBSIs). This is a recognized unmet medical need, as there have been no large scale studies to provide robust evidence on the effectiveness of antibiotic lock therapies.
The company's Mino-Lok product contains a proprietary combination of minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter.
Citius is dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care, and unique prescription products that use innovative, patented or proprietary formulations of previously-approved active pharmaceutical ingredients.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer